Successful establishment and evaluation of a new animal model for studying the hepatitis B virus YVDD mutant

详细信息    查看全文

• 作者：Yan-Xiu Ma (1)
  Zhi-Wei Song (1) (2)
  Xu Teng (1)
  Li-Juan Fu (1) (3)
  Mei-Li Hao (1)
  Si-Jia Chen (1)
  Wei-Zhen Xu (1)
  Hong-Xi Gu (1)
  
• 刊名：Archives of Virology
• 出版年：2013
• 出版时间：April 2013
• 年：2013
• 卷：158
• 期：4
• 页码：785-791
• 全文大小：2292KB
• 参考文献：1. Nebbia G, Peppa D, Maini MK (2012) Hepatitis B infection: current concepts and future challenges. QJM 105:109鈥?13 CrossRef
  2. Yuan HJ, Lee WM (2007) Molecular mechanisms of resistance to antiviral therapy in patients with chronic hepatitis B. Curr Mol Med 7:185鈥?97 CrossRef
  3. Hayashi K, Katano Y, Ishigami M, Itoh A, Hirooka Y, Nakano I, Yoshioka K, Yano M, Toyoda H, Kumada T, Goto H (2010) Prevalence and clinical characterization of patients with acute hepatitis B induced by lamivudine-resistant strains. J Gastroenterol Hepatol 25:745鈥?49 CrossRef
  4. Fung J, Lai CL, Seto WK, Yuen MF (2011) Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B. J Antimicrob Chemother 66:2715鈥?725 CrossRef
  5. Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, Brown N, Woessner M, Boehme R, Condreay L (2003) Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 36:687鈥?96 CrossRef
  6. Zoulim F, Locarnini S (2009) Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 137(1593鈥?608):e1591鈥揺1592
  7. Hashimoto Y, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saito S, Suzuki Y, Arase Y, Ikeda K, Kumada H (2010) Clinical and virological effects of long-term (over 5聽years) lamivudine therapy. J Med Virol 82:684鈥?91 CrossRef
  8. Lau DT, Khokhar MF, Doo E, Ghany MG, Herion D, Park Y, Kleiner DE, Schmid P, Condreay LD, Gauthier J, Kuhns MC, Liang TJ, Hoofnagle JH (2000) Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 32:828鈥?34 CrossRef
  9. Dandri M, Lutgehetmann M, Volz T, Petersen J (2006) Small animal model systems for studying hepatitis B virus replication and pathogenesis. Semin Liver Dis 26:181鈥?91 CrossRef
  10. Jin Z, Sun R, Wei H, Gao X, Chen Y, Tian Z (2010) Accelerated liver fibrosis in hepatitis B virus transgenic mice: involvement of natural killer T cells. Hepatology 53:219鈥?29 CrossRef
  11. Guo Y, Ren D, He X, Wang F, Jiang L, Song S, He Y, Sun S (2009) A novel mouse model for immunogenic evaluation of human HBV vaccines. Vaccine 27:5692鈥?699 CrossRef
  12. Lutgehetmann M, Mancke LV, Volz T, Helbig M, Allweiss L, Bornscheuer T, Pollok JM, Lohse AW, Petersen J, Urban S, Dandri M (2012) Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation. Hepatology 55:685鈥?94 CrossRef
  13. Tsuge M, Takahashi S, Hiraga N, Fujimoto Y, Zhang Y, Mitsui F, Abe H, Kawaoka T, Imamura M, Ochi H, Hayes CN, Chayama K (2011) Effects of hepatitis B virus infection on the interferon response in immunodeficient human hepatocyte chimeric mice. J Infect Dis 204:224鈥?28 CrossRef
  14. Liu F, Song Y, Liu D (1999) Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 6:1258鈥?266 CrossRef
  15. Yang PL, Althage A, Chung J, Chisari FV (2002) Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection. Proc Natl Acad Sci USA 99:13825鈥?3830 CrossRef
  16. Deng L, Li G, Xi L, Yin A, Gao Y, You W, Wang X, Sun B (2009) Hepatitis B virus inhibition in mice by lentiviral vector mediated short hairpin RNA. BMC Gastroenterol 9:73 CrossRef
  17. Gao Z, Liu FJ, Liu L, Zhou TY, Lei J, Xu L, Liu C, Dai J, Chen EQ, Tang H (2010) Application of hepatitis B virus replication mouse model. World J Gastroenterol 16:1979鈥?985 CrossRef
  18. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, Brown N, Condreay LD (1998) Identification and characterization of mutations in hepatitis B virus resistant to lamivudine: Lamivudine Clinical Investigation Group. Hepatology 27:1670鈥?677 CrossRef
  19. Ono SK, Kato N, Shiratori Y, Kato J, Goto T, Schinazi RF, Carrilho FJ, Omata M (2001) The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest 107:449鈥?55 CrossRef
  20. Delaney WET, Yang H, Westland CE, Das K, Arnold E, Gibbs CS, Miller MD, Xiong S (2003) The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol 77:11833鈥?1841 CrossRef
  21. Moriyama K, Okamoto H, Tsuda F, Mayumi M (1996) Reduced precore transcription and enhanced core-pregenome transcription of hepatitis B virus DNA after replacement of the precore-core promoter with sequences associated with e antigen-seronegative persistent infections. Virology 226:269鈥?80 CrossRef
  22. Liao Y, Hu X, Chen J, Cai B, Tang J, Ying B, Wang H, Wang L (2012) Precore mutation of hepatitis B virus may contribute to hepatocellular carcinoma risk: evidence from an updated meta-analysis. PLoS ONE 7:e38394 CrossRef
  23. Asahina Y, Izumi N, Uchihara M, Noguchi O, Nishimura Y, Inoue K, Ueda K, Tsuchiya K, Hamano K, Itakura J, Miyake S (2003) Core promoter/pre-core mutations are associated with lamivudine-induced HBeAg loss in chronic hepatitis B with genotype C. J Hepatol 39:1063鈥?069 CrossRef
  
• 作者单位：Yan-Xiu Ma (1)
  Zhi-Wei Song (1) (2)
  Xu Teng (1)
  Li-Juan Fu (1) (3)
  Mei-Li Hao (1)
  Si-Jia Chen (1)
  Wei-Zhen Xu (1)
  Hong-Xi Gu (1)
  
  1. Department of Microbiology, The Heilongjiang Key Laboratory of Immunity and Infection, Pathogenic Biology, Harbin Medical University, 157 Baojian Road, Nangang, Harbin, Heilongjing, 150081, China
  2. Laboratory Diagnosis Department, The First Affiliated Hospital of Harbin Medical University, 199 Xidazhi Street Nangang, Harbin, 150001, China
  3. Department of Infectious Diseases, Heilongjiang Province Hospital, 82 Zhongshan Road, Xiangfang, Harbin, 150001, China
  
• ISSN：1432-8798

文摘

The treatment of infection with lamivudine-resistant mutants of hepatitis B virus (HBV) with mutations in the YMDD motif has become a crucial issue in the clinic. In this work, the plasmids pcDNA3.1 (+)-HBV/C-YVDD and pcDNA3.1 (+)-HBV/C-YMDD were constructed and injected into BALB/c mice using a hydrodynamics-based procedure to investigate viral replication and expression of HBV lamivudine-resistant YVDD mutants in vivo. Compared with the YMDD group, HBsAg levels were higher in sera of mice in the YVDD group, but HBeAg levels were lower on day 1 after injection. Levels of HBcAg in hepatocytes were higher in the YVDD group on day 1, whereas the HBsAg levels were lower. The levels of HBV mRNA in the liver were higher in mice in the YVDD group on day 1 after injection. The results showed that injection with these plasmids resulted in efficient initiation of replication of HBV in mice and also suggested that the combined mutations in YVDD mutants could affect the replication process.